Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A Phase (ph) 1b/2 Study of TAK-659, an Investigational Dual FLT-3 and SYK Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Keith Pratz, MD, Mark J. Levis, MD, John C Morris, MD, Trisha Wise-Draper, MD PhD, Moshe Levy, MD, Dale L. Bixby, Patrick Burke, MD, Daniela Hernandez, MD, Kate Stumpo, BA, Karuppiah Kannan, Emily Sheldon-Waniga, PhD, Shining Wang, MD, Steven Zhang, PhD, Yaping Shou, MD PhD, Jessica K. Altman, MD, Jason Kaplan, MD, Olga Frankfurt, MD

Blood (2017) 130 (Supplement 1): 2622.

https://doi.org/10.1182/blood.V130.Suppl_1.2622.2622

Published: 2017

Journal Articles

a Phase 1b/2 Study of TAK-659, an Investigational Dual SYK and FLT-3 Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Jason B Kaplan, MD, Dale L. Bixby, MD, John C Morris, MD, Olga Frankfurt, MD, Jessica Altman, Trisha Wise-Draper, MD PhD, Patrick W. Burke, MD, Sabrina Collins, BS, Karuppiah Kannan, PhD, Ling Wang, PhD, Stephanie Faucette, PharmD, PhD, Benjamin Lee, MD PhD, Yaping Shou, MD PhD, Mark J. Levis, MD PhD, Keith W. Pratz, MD

Blood (2016) 128 (22): 2834.

https://doi.org/10.1182/blood.V128.22.2834.2834

Published: 2016

Journal Articles

Alemtuzumab (Campath 1-H) in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma.

Kamal Sharma, DO, John E. Janik, MD, Deirdre O’Mahony, MD, Donn Stewart, MD, Stefania Pittaluga, MD, Maryalice Stetler-Stevenson, MD, PhD, Elaine S. Jaffe, MD, Mark Raffeld, MD, Thomas A. Fleisher, MD, Cathryn C. Lee, NP, Nicole Urquhart, MD, Seth Steinberg, PhD, Thomas A. Waldmann, MD, John C. Morris, MD

Blood (2008) 112 (11): 2010.

https://doi.org/10.1182/blood.V112.11.2010.2010

Published: 2008

Journal Articles

Yttrium-90 Radiolabeled Humanized Monoclonal Antibody to CD25 in Refractory and Relapsed Hodgkin’s Lymphoma

Deirdre O’Mahony, MD, John E Janik, MD, Jorge A. Carrasquillo, MD, Pamela Seam, MD, Joseph A Fiorillo, MD, Donn Stewart, MD, Chang H Paik, PhD, Suzanne Fioravanti, RN, Millie Whatley, RNMT, Stefania Pittaluga, MD, PhD, Martin W Brechbiel, PhD, John C Morris, MD, Thomas A Waldmann, MD

Blood (2008) 112 (11): 231.

https://doi.org/10.1182/blood.V112.11.231.231

Published: 2008

Journal Articles

EBV-Related Lymphoproliferative Disease Complicating Therapy with Siplizumab, a Novel Anti-CD2 Mediated T- and NK-Cell Depleting Agent, in Patients with T-Cell Malignancies.

Deirdre O’Mahony, MD, John C. Morris, MD, Maryalice Stetler-Stevenson, MD, Helen Matthews, RN, Stefania Pittaluga, MD, Paul Albert, PhD, Karen Kaucic, MD, Luz Hammershaimb, MD, Thomas A. Waldmann, MD, John E. Janik, MD

Blood (2007) 110 (11): 3565.

https://doi.org/10.1182/blood.V110.11.3565.3565

Published: 2007

Journal Articles

Phase I Trial of Siplizumab in CD2-Positive Lymphoproliferative Disease.

Deirdre O’Mahony, MD, John C. Morris, MD, Leslie Moses, Diana O’Hagan, Wendy Gao, Maryalice Stetler-Stevenson, MD, Margaret Taylor, Luz Hammershaimb, MD, Thomas A. Waldmann, John E. Janik, MD

Blood (2005) 106 (11): 3353.

https://doi.org/10.1182/blood.V106.11.3353.3353

Published: 2005

Journal Articles

Interaction of Measles Virus Vectors with Auger Electron Emitting Radioisotopes.

David Dingli, MD, PhD, Kah-Whye Peng, PhD, Mary E. Harvey, Sompong Vongpunsawad, Elizabeth R. Bergert, Robert A. Kyle, MD, Roberto Cattaneo, PhD, John C. Morris, MD, Stephen J. Russell, MD, PhD

Blood (2005) 106 (11): 5525.

https://doi.org/10.1182/blood.V106.11.5525.5525

Published: 2005

NARROW

A Phase (ph) 1b/2 Study of TAK-659, an Investigational Dual FLT-3 and SYK Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

a Phase 1b/2 Study of TAK-659, an Investigational Dual SYK and FLT-3 Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Alemtuzumab (Campath 1-H) in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma.

Yttrium-90 Radiolabeled Humanized Monoclonal Antibody to CD25 in Refractory and Relapsed Hodgkin’s Lymphoma

EBV-Related Lymphoproliferative Disease Complicating Therapy with Siplizumab, a Novel Anti-CD2 Mediated T- and NK-Cell Depleting Agent, in Patients with T-Cell Malignancies.

Phase I Trial of Siplizumab in CD2-Positive Lymphoproliferative Disease.

Interaction of Measles Virus Vectors with Auger Electron Emitting Radioisotopes.

Email alerts

ASH Publications

American Society of Hematology

A Phase (ph) 1b/2 Study of TAK-659, an Investigational Dual FLT-3 and SYK Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

a Phase 1b/2 Study of TAK-659, an Investigational Dual SYK and FLT-3 Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Alemtuzumab (Campath 1-H) in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma.

Yttrium-90 Radiolabeled Humanized Monoclonal Antibody to CD25 in Refractory and Relapsed Hodgkin’s Lymphoma

EBV-Related Lymphoproliferative Disease Complicating Therapy with Siplizumab, a Novel Anti-CD2 Mediated T- and NK-Cell Depleting Agent, in Patients with T-Cell Malignancies.

Phase I Trial of Siplizumab in CD2-Positive Lymphoproliferative Disease.

Interaction of Measles Virus Vectors with Auger Electron Emitting Radioisotopes.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only